Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

Pathogenesis and Management of Acute Kidney Injury in Patients with Nephrotic Syndrome Due to Primary Glomerulopathies.

Lionaki S, Liapis G, Boletis JN.

Medicina (Kaunas). 2019 Jul 11;55(7). pii: E365. doi: 10.3390/medicina55070365. Review.

2.

Impact of Primary Disease Nature in the Development of De Novo Donor-Specific Antibodies After Kidney Transplant and the Risk of Acute Rejection.

Lionaki S, Pappas A, Altanis N, Kapsia H, Liapis G, Vittoraki A, Iniotaki A, Zavos G, Boletis JN.

Exp Clin Transplant. 2019 Jun;17(3):304-312. doi: 10.6002/ect.2018.0054. Epub 2018 Oct 24.

3.

Primary Hepatic Burkitt Lymphoma in a Kidney Transplant Recipient.

Lionaki S, Tsakonas E, Androulaki A, Liapis G, Panayiotidis P, Zavos G, Boletis JN.

Case Rep Nephrol. 2018 May 13;2018:7425785. doi: 10.1155/2018/7425785. eCollection 2018.

4.

Stress and Disease Onset in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.

Golemati CV, Mavragani CP, Lionaki S, Karaiskos D, Moutsopoulos HM.

Front Psychiatry. 2017 Dec 15;8:286. doi: 10.3389/fpsyt.2017.00286. eCollection 2017.

5.

Central nervous system involvement in patients with granulomatosis with polyangiitis: a single-center retrospective study.

Fragoulis GE, Lionaki S, Venetsanopoulou A, Vlachoyiannopoulos PG, Moutsopoulos HM, Tzioufas AG.

Clin Rheumatol. 2018 Mar;37(3):737-747. doi: 10.1007/s10067-017-3835-y. Epub 2017 Sep 15.

PMID:
28914375
6.

The clinical course of IgA nephropathy after kidney transplantation and its management.

Lionaki S, Panagiotellis K, Melexopoulou C, Boletis JN.

Transplant Rev (Orlando). 2017 Apr;31(2):106-114. doi: 10.1016/j.trre.2017.01.005. Epub 2017 Feb 2. Review.

PMID:
28209246
7.

Cyclophosphamide followed by rituximab for aggressive multiple-relapsing antineutrophil cytoplasmic antibody-associated vasculitis.

Lionaki S, Fragoulis GE, Venetsanopoulou A, Vlachoyiannopoulos P, Boletis JN, Tzioufas AG.

Clin Exp Rheumatol. 2017 Mar-Apr;35 Suppl 103(1):155-164. Epub 2017 Jan 25.

PMID:
28134075
8.

The Prevalence and Management of Pauci-Immune Glomerulonephritis and Vasculitis in Western Countries.

Lionaki S, Boletis JN.

Kidney Dis (Basel). 2016 Mar;1(4):224-34. doi: 10.1159/000442062. Epub 2015 Dec 5. Review.

9.

Understanding the complement-mediated glomerular diseases: focus on membranoproliferative glomerulonephritis and C3 glomerulopathies.

Lionaki S, Gakiopoulou H, Boletis JN.

APMIS. 2016 Sep;124(9):725-35. doi: 10.1111/apm.12566. Epub 2016 Jun 30. Review.

PMID:
27356907
10.

Predictors of renal histopathology in antineutrophil cytoplasmic antibody associated glomerulonephritis.

Lionaki S, Mavragani CP, Karras A, Liapis G, Somarakis G, Boletis JN, Drosos A, Tzioufas AG, Guillevin L, Moutsopoulos HM.

J Autoimmun. 2016 Aug;72:57-64. doi: 10.1016/j.jaut.2016.05.004. Epub 2016 May 15.

PMID:
27194577
11.

Patients with primary membranous nephropathy are at high risk of cardiovascular events.

Lee T, Derebail VK, Kshirsagar AV, Chung Y, Fine JP, Mahoney S, Poulton CJ, Lionaki S, Hogan SL, Falk RJ, Cattran DC, Hladunewich M, Reich HN, Nachman PH.

Kidney Int. 2016 May;89(5):1111-1118. doi: 10.1016/j.kint.2015.12.041. Epub 2016 Feb 26.

12.

De Novo Visceral Malignancies in Renal Transplant Recipients: A Single Center Experience of 2054 Recipients for More Than 30 Years.

Zavos G, Moris D, Kostakis ID, Vernadakis S, Bokos J, Zavvos V, Lionaki S, Boletis J.

Exp Clin Transplant. 2015 Aug;13(4):313-8.

13.

Evolution of Renal Function in Renal Allograft Recipients Under Various Everolimus-Based Immunosuppressive Regimens.

Skalioti C, Marinaki S, Darema M, Lionaki S, Antonakopoulos N, Zavos G, Boletis J.

Transplant Proc. 2015 Jul-Aug;47(6):1705-10. doi: 10.1016/j.transproceed.2015.05.029.

PMID:
26293038
14.

A Cytomegalovirus-related Pseudotumor in the Colon of A Renal Transplant Recipient Shrunk by Antiviral Therapy.

Lionaki S, Altanis N, Papaxoinis K, Delladetsima I, Daikos G, Boletis JN.

Transplantation. 2015 Jul;99(7):e46-7. doi: 10.1097/TP.0000000000000772. No abstract available.

PMID:
26147137
15.

Urine NGAL as a biomarker of kidney damage after on- and off-pump coronary artery bypass graft surgery: a prospective pilot study.

Karaolanis G, Katsaros A, Palla VV, Lionaki S, Moris D, Karanikola E, Kravaritou M, Drossos V, Psarros T, Triantafillou K, Aleksandropoulos N, Zografos G.

Hellenic J Cardiol. 2015 Mar-Apr;56(2):160-8.

16.

Individualized scheme of immunoadsorption for the recurrence of idiopathic focal segmental glomerulosclerosis in the graft: a single center experience.

Lionaki S, Vlachopanos G, Georgalis A, Liapis G, Skalioti C, Zavos G, Boletis JN.

Ren Fail. 2015 Jun;37(5):777-83. doi: 10.3109/0886022X.2015.1015366. Epub 2015 Feb 26.

PMID:
25715638
17.

Clostridium difficile infection among kidney transplant recipients: frequency, clinical presentation, and outcome.

Lionaki S, Panagiotellis K, Moris D, Daikos G, Psyhogiou M, Vernadakis S, Zavos G, Boletis JN.

APMIS. 2015 Mar;123(3):234-9. doi: 10.1111/apm.12348. Epub 2014 Dec 31.

PMID:
25556694
18.

Incidence and management of Kaposi sarcoma in renal transplant recipients: the Greek experience.

Zavos G, Moris D, Vernadakis S, Bokos J, Lionaki S, Mamarelis G, Panagiotellis K, Zavvos V, Boletis I.

Transplant Proc. 2014 Nov;46(9):3199-202. doi: 10.1016/j.transproceed.2014.09.165.

PMID:
25420858
19.

Kidney transplantation in patients with systemic lupus erythematosus.

Lionaki S, Skalioti C, Boletis JN.

World J Transplant. 2014 Sep 24;4(3):176-82. doi: 10.5500/wjt.v4.i3.176. Review.

20.

Secondary hyperoxaluria: a risk factor for kidney stone formation and renal failure in native kidneys and renal grafts.

Karaolanis G, Lionaki S, Moris D, Palla VV, Vernadakis S.

Transplant Rev (Orlando). 2014 Oct;28(4):182-7. doi: 10.1016/j.trre.2014.05.004. Epub 2014 May 27. Review.

PMID:
24999029
21.

Predictors of treatment outcomes in ANCA-associated vasculitis with severe kidney failure.

Lee T, Gasim A, Derebail VK, Chung Y, McGregor JG, Lionaki S, Poulton CJ, Hogan SL, Jennette JC, Falk RJ, Nachman PH.

Clin J Am Soc Nephrol. 2014 May;9(5):905-13. doi: 10.2215/CJN.08290813. Epub 2014 Feb 27.

22.

Kidney transplantation outcomes from expanded criteria donors, standard criteria donors or living donors older than 60 years.

Lionaki S, Kapsia H, Makropoulos I, Metsini A, Skalioti C, Gakiopoulou H, Zavos G, Boletis JN.

Ren Fail. 2014 May;36(4):526-33. doi: 10.3109/0886022X.2013.876348. Epub 2014 Jan 23.

PMID:
24456131
23.

Incidence and clinical significance of de novo donor specific antibodies after kidney transplantation.

Lionaki S, Panagiotellis K, Iniotaki A, Boletis JN.

Clin Dev Immunol. 2013;2013:849835. doi: 10.1155/2013/849835. Epub 2013 Nov 21. Review.

24.

Personalized prophylactic anticoagulation decision analysis in patients with membranous nephropathy.

Lee T, Biddle AK, Lionaki S, Derebail VK, Barbour SJ, Tannous S, Hladunewich MA, Hu Y, Poulton CJ, Mahoney SL, Charles Jennette J, Hogan SL, Falk RJ, Cattran DC, Reich HN, Nachman PH.

Kidney Int. 2014 Jun;85(6):1412-20. doi: 10.1038/ki.2013.476. Epub 2013 Dec 11.

25.

An uncommon cause of acutely altered mental status in a renal transplant recipient.

Moris D, Vernadakis S, Lionaki S, Daikos G, Zavos G.

Ups J Med Sci. 2014 Mar;119(1):50-4. doi: 10.3109/03009734.2013.842618. Epub 2013 Sep 30.

26.

Depletion of B lymphocytes in idiopathic membranous glomerulopathy: results from patients with extended follow-up.

Lionaki S, Marinaki S, Nakopoulou L, Skalioti C, Iniotaki A, Sfikakis PP, Siamopoulos C, Boletis J.

Nephron Extra. 2013 Jan;3(1):1-11. doi: 10.1159/000345487. Epub 2013 Jan 5.

27.

Glomerular disease recurrence in the renal allograft: a hurdle but not a barrier for successful kidney transplantation.

Marinaki S, Lionaki S, Boletis JN.

Transplant Proc. 2013 Jan-Feb;45(1):3-9. doi: 10.1016/j.transproceed.2012.12.021. Review.

PMID:
23375268
28.

Lupus nephritis and non-Hodgkin lymphoma simultaneously diagnosed in a patient on methimazole.

Lionaki S, Vlachopanos G, Georgalis A, Ziakas P, Gakiopoulou H, Petra C, Boletis J.

Lupus. 2013 Jan;22(1):95-8. doi: 10.1177/0961203312467668.

PMID:
23263868
29.

Classification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis.

Lionaki S, Blyth ER, Hogan SL, Hu Y, Senior BA, Jennette CE, Nachman PH, Jennette JC, Falk RJ.

Arthritis Rheum. 2012 Oct;64(10):3452-62. doi: 10.1002/art.34562.

30.

Venous thromboembolism in patients with membranous nephropathy.

Lionaki S, Derebail VK, Hogan SL, Barbour S, Lee T, Hladunewich M, Greenwald A, Hu Y, Jennette CE, Jennette JC, Falk RJ, Cattran DC, Nachman PH, Reich HN.

Clin J Am Soc Nephrol. 2012 Jan;7(1):43-51. doi: 10.2215/CJN.04250511. Epub 2011 Nov 10.

31.

The clinical course of ANCA small-vessel vasculitis on chronic dialysis.

Lionaki S, Hogan SL, Jennette CE, Hu Y, Hamra JB, Jennette JC, Falk RJ, Nachman PH.

Kidney Int. 2009 Sep;76(6):644-51. doi: 10.1038/ki.2009.218. Epub 2009 Jun 17.

32.

Inhibition of tumour necrosis factor alpha in idiopathic membranous nephropathy: a pilot study.

Lionaki S, Siamopoulos K, Theodorou I, Papadimitraki E, Bertsias G, Boumpas D, Boletis J.

Nephrol Dial Transplant. 2009 Jul;24(7):2144-50. doi: 10.1093/ndt/gfn771. Epub 2009 Feb 7.

PMID:
19202167
33.

Rituximab and mycophenolate mofetil for relapsing proliferative lupus nephritis: a long-term prospective study.

Boletis JN, Marinaki S, Skalioti C, Lionaki SS, Iniotaki A, Sfikakis PP.

Nephrol Dial Transplant. 2009 Jul;24(7):2157-60. doi: 10.1093/ndt/gfp002. Epub 2009 Jan 29.

PMID:
19179411
34.

Antibodies with dual reactivity to plasminogen and complementary PR3 in PR3-ANCA vasculitis.

Bautz DJ, Preston GA, Lionaki S, Hewins P, Wolberg AS, Yang JJ, Hogan SL, Chin H, Moll S, Jennette JC, Falk RJ.

J Am Soc Nephrol. 2008 Dec;19(12):2421-9. doi: 10.1681/ASN.2008030270. Epub 2008 Aug 13.

35.

Kidney transplantation in lupus patients: a case-control study from a single centre.

Lionaki S, Kapitsinou PP, Iniotaki A, Kostakis A, Moutsopoulos HM, Boletis JN.

Lupus. 2008 Jul;17(7):670-5. doi: 10.1177/0961203308089430.

PMID:
18625640
36.

ANCA patients have T cells responsive to complementary PR-3 antigen.

Yang J, Bautz DJ, Lionaki S, Hogan SL, Chin H, Tisch RM, Schmitz JL, Pressler BM, Jennette JC, Falk RJ, Preston GA.

Kidney Int. 2008 Nov;74(9):1159-69. doi: 10.1038/ki.2008.309. Epub 2008 Jul 2.

37.

Vasculitis and anti-thyroid medication.

Lionaki S, Hogan SL, Falk RJ, Joy MS, Jennette CE, Nachman PH, Jennette JC.

Nephrol Dial Transplant. 2008 May;23(5):1766-8; author reply 1768. doi: 10.1093/ndt/gfm887. Epub 2007 Dec 21. No abstract available.

38.

Plasma exchange led to a higher rate of renal recovery than intravenous methylpredisolone in severe vasculitis.

Lionaki S, Falk RJ.

ACP J Club. 2008 Jan-Feb;148(1):11. No abstract available.

PMID:
18170998
39.

Anti-neutrophil cytoplasmic (ANCA) and anti-glomerular basement membrane (GBM) autoantibodies in necrotizing and crescentic glomerulonephritis.

Lionaki S, Jennette JC, Falk RJ.

Semin Immunopathol. 2007 Nov;29(4):459-74. Epub 2007 Oct 18. Review.

PMID:
17943286
40.

Association of silica exposure with anti-neutrophil cytoplasmic autoantibody small-vessel vasculitis: a population-based, case-control study.

Hogan SL, Cooper GS, Savitz DA, Nylander-French LA, Parks CG, Chin H, Jennette CE, Lionaki S, Jennette JC, Falk RJ.

Clin J Am Soc Nephrol. 2007 Mar;2(2):290-9. Epub 2007 Feb 7.

41.

Association between thyroid disease and its treatment with ANCA small-vessel vasculitis: a case-control study.

Lionaki S, Hogan SL, Falk RJ, Joy MS, Chin H, Jennette CE, Jennette JC, Nachman PH.

Nephrol Dial Transplant. 2007 Dec;22(12):3508-15. Epub 2007 Aug 8.

PMID:
17686815
42.

Leukocyte gene expression signatures in antineutrophil cytoplasmic autoantibody and lupus glomerulonephritis.

Alcorta DA, Barnes DA, Dooley MA, Sullivan P, Jonas B, Liu Y, Lionaki S, Reddy CB, Chin H, Dempsey AA, Jennette JC, Falk RJ.

Kidney Int. 2007 Oct;72(7):853-64. Epub 2007 Aug 1.

43.

Removing antibody and preserving glomeruli in ANCA small-vessel vasculitis.

Lionaki S, Falk RJ.

J Am Soc Nephrol. 2007 Jul;18(7):1987-9. No abstract available.

44.

Reconstructive surgery for kidney transplant recipients.

Papadopoulos O, Konofaos P, Chrisostomidis C, Lionaki S, Georgiou P, Vlasis K, Kostakis A.

Transplant Proc. 2005 Dec;37(10):4218-22.

PMID:
16387082
45.

Delayed renal graft function: the influence of immunosuppression.

Boletis J, Balitsari A, Filiopoulos V, Stamataki E, Lionaki S, Zavos G, Kostakis A.

Transplant Proc. 2005 Jun;37(5):2054-9.

PMID:
15964337
46.

Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial.

Sfikakis PP, Boletis JN, Lionaki S, Vigklis V, Fragiadaki KG, Iniotaki A, Moutsopoulos HM.

Arthritis Rheum. 2005 Feb;52(2):501-13.

47.

Cyclosporine levels at 2 hours after dose and body mass index in relation to graft function in renal transplant patients treated with azathioprine or mycophenolate mofetil.

Konstadinidou I, Giapraka N, Lionaki S, Kyriaki-Manolaraki D, Kostakis A, Stathakis CP, Boletis JN.

Transplant Proc. 2004 Jul-Aug;36(6):1753-6.

PMID:
15350469

Supplemental Content

Loading ...
Support Center